ACRS
Aclaris Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$5.50
+1.85%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.17
- Revenue estimate
- $1.3M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.15
- EPS estimate
- -$0.16
- Revenue actual
- $1.6M
- Revenue estimate
- $1.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +3.2%
- Revenue beats (12Q)
- 7
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.16 | -$0.15 | Beat 6.25% | $1.6M |
| May 7, 2026 | -$0.16 | -$0.15 | Beat 6.25% | $2.0M |
| Feb 26, 2026 | -$0.15 | -$0.16 | Miss -7.58% | $1.3M |
| Nov 6, 2025 | -$0.13 | -$0.12 | Beat 7.69% | $3.3M |
| Aug 7, 2025 | -$0.13 | -$0.13 | In line | $1.8M |
| May 8, 2025 | -$0.17 | -$0.12 | Beat 29.41% | $1.5M |
| Feb 27, 2025 | -$0.09 | -$0.10 | Miss -11.11% | $9.2M |
| Feb 27, 2024 | -$0.37 | -$0.30 | Beat 18.92% | $17.6M |
| Feb 23, 2023 | -$0.46 | -$0.41 | Beat 10.87% | $7.8M |
| Aug 3, 2022 | -$0.36 | -$0.31 | Beat 13.89% | $1.5M |
| Feb 24, 2022 | -$0.36 | -$0.37 | Miss -2.78% | $1.5M |
| Nov 2, 2021 | -$0.27 | -$0.35 | Miss -29.63% | $1.7M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026